yes, seems a valid criticism.

Either:

1) the trial results on the last 50% of CD12 patients was significantly different than the trial results on the first 50% of patients

or

2) the DSMC was incompetent

#2 is suggested by the poor results on the 75 patients who did not receive either dexamethasone or other common covid treatments.

Seems to me unlikely that the 75 patients were in the second 50%.

By the time of the second 50%, everyone knew about dexamethasone and new covid treatments.

Seems to me those 75 patients were in the first 50%, when the DSMC looked and said "Continue your trial."

But the poorest results were on these first 75 patients so the 50% interim look would have included those 75 poor performing patients.

I don't get it.